Social and structural determinants of HAART access and adherence among injection drug users

被引:106
作者
Kruesi, Andrea [1 ]
Wood, Evan [1 ,2 ]
Montaner, Julio [1 ,2 ]
Kerr, Thomas [1 ,2 ]
机构
[1] St Pauls Hosp, BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[2] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada
关键词
Drug users; HIV treatment; HAART; ARV; Access; Adherence; ACTIVE ANTIRETROVIRAL THERAPY; HIV TREATMENT; CASE-MANAGEMENT; TRANSITIONAL COUNTRIES; MEDICATION ADHERENCE; SUBSTANCE-ABUSE; CELL COUNTS; CARE; WOMEN; SURVIVAL;
D O I
10.1016/j.drugpo.2009.08.003
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Highly active antiretroviral therapy (HAART) has dramatically improved health outcomes among people living with HIV/AIDS. However, significant rates of HIV-related morbidity and mortality have persisted among HIV-positive injection drug users (IDU) globally. To date, research as well as programmatic and policy responses have failed to adequately address barriers to HAART access and adherence among IDU both in developing/transitional and developed countries. A review of existing literature suggests that this is due to a shortage of context-specific evidence and an overemphasis on individual-level and behavioural variables. We propose a conceptual shift away from understanding suboptimal HAART adherence as determined predominantly by individual factors modifiable through individually focused interventions, towards a greater acknowledgement of the influence of social and structural factors such as stigmatization and social exclusion, unstable housing environments, the organization of health care systems and the continued prohibitionist approach to illicit drug policy. Globally, the future of a successful HAART treatment approach for HIV-positive IDU relies largely on a more careful consideration of these social and structural barriers that IDU face and, importantly, on a serious commitment to effect social and structural changes that will foster conditions which allow IDU to enjoy the full benefits of HAART. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:4 / 9
页数:6
相关论文
共 90 条
[1]   Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the 'Treating 3 million by 2005. Making it happen. The WHO strategy' ('3by5') [J].
Aceijas, Carmen ;
Oppenheimer, Edna ;
Stimson, Gerry V. ;
Ashcroft, Richard E. ;
Matic, Srdan ;
Hickman, Matthew .
ADDICTION, 2006, 101 (09) :1246-1253
[2]  
Andersen M D, 1999, J Assoc Nurses AIDS Care, V10, P55, DOI 10.1016/S1055-3290(06)60299-9
[3]  
[Anonymous], 1986, Heal Promot, V1
[4]  
[Anonymous], HIV AIDS TREATM CAR
[5]  
[Anonymous], RHET RISK HUM RIGHTS
[6]   Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users [J].
Arnsten, Julia H. ;
Li, Xuan ;
Mizuno, Yuko ;
Knowlton, Amy R. ;
Gourevitch, Marc N. ;
Handley, Kathleen ;
Knight, Kelly R. ;
Metsch, Lisa R. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 :S64-S71
[7]   Protease inhibitors in the homeless [J].
Bangsberg, D ;
Tulsky, JP ;
Hecht, FM ;
Moss, AR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (01) :63-65
[8]  
Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114
[9]  
Baumohl J., 2003, CONTEMP DRUG PROBL, V30, P501
[10]   Clinical care of the HIV-infected drug user [J].
Bruce, R. Douglas ;
Altice, Frederick L. .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2007, 21 (01) :149-+